TY - JOUR T1 - Circulating Long Non-coding RNAs in Plasma of Patients with Gastric Cancer JF - Anticancer Research JO - Anticancer Res SP - 3185 LP - 3193 VL - 33 IS - 8 AU - TOMOHIRO ARITA AU - DAISUKE ICHIKAWA AU - HIROTAKA KONISHI AU - SHUHEI KOMATSU AU - ATSUSHI SHIOZAKI AU - KATSUTOSHI SHODA AU - TSUTOMU KAWAGUCHI AU - SHOJI HIRAJIMA AU - HIROAKI NAGATA AU - TAKESHI KUBOTA AU - HITOSHI FUJIWARA AU - KAZUMA OKAMOTO AU - EIGO OTSUJI Y1 - 2013/08/01 UR - http://ar.iiarjournals.org/content/33/8/3185.abstract N2 - Background: We examined the levels of long non-coding RNAs (lncRNAs) in the plasma of patients with gastric cancer to assess their clinical significance for diseases diagnosing and monitoring. Materials and Methods: We investigated the stability of plasma lncRNAs, and then confirmed the appropriateness of the lncRNA assay with a pre-amplification method. The levels of plasma lncRNAs, H19, HOX antisense intergenic RNA (HOTAIR), and metastasis associated lung adenocarcinoma transcript-1 (MALAT1), were then analyzed in patients with gastric cancer (GC) and healthy controls. Results: Plasma lncRNAs exhibited minimal gradual instability only under several severe conditions. Analysis showed that samples with pre-amplification had a higher level of linearity in the reverse transcription polymerase chain reaction (RT-PCR) assay than those without pre-amplification. Plasma H19 levels were significantly higher in patients than in healthy controls. Plasma H19 levels were significantly reduced in postoperative samples. Conclusion: Circulating lncRNAs can be detectable in plasma, and the detection of circulating lncRNAs may provide new complementary tumor markers for gastric cancer. ER -